Coldstream Capital Management Inc. Makes New $280,000 Investment in DaVita Inc. (NYSE:DVA)

Coldstream Capital Management Inc. purchased a new position in shares of DaVita Inc. (NYSE:DVA) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 2,676 shares of the company’s stock, valued at approximately $280,000.

Several other institutional investors also recently added to or reduced their stakes in DVA. Vanguard Group Inc. increased its holdings in shares of DaVita by 1.1% in the third quarter. Vanguard Group Inc. now owns 6,175,029 shares of the company’s stock valued at $583,725,000 after purchasing an additional 65,526 shares during the period. Invesco Ltd. increased its holdings in shares of DaVita by 21.3% in the third quarter. Invesco Ltd. now owns 1,667,255 shares of the company’s stock valued at $157,606,000 after purchasing an additional 292,767 shares during the period. Deutsche Bank AG increased its holdings in shares of DaVita by 421.8% in the third quarter. Deutsche Bank AG now owns 1,095,081 shares of the company’s stock valued at $103,518,000 after purchasing an additional 885,195 shares during the period. Lazard Asset Management LLC increased its holdings in shares of DaVita by 8.7% in the third quarter. Lazard Asset Management LLC now owns 845,416 shares of the company’s stock valued at $79,916,000 after purchasing an additional 67,970 shares during the period. Finally, Northern Trust Corp increased its holdings in shares of DaVita by 15.7% in the third quarter. Northern Trust Corp now owns 834,608 shares of the company’s stock valued at $78,895,000 after purchasing an additional 113,508 shares during the period. Institutional investors and hedge funds own 90.12% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on DVA shares. Barclays boosted their target price on DaVita from $133.00 to $150.00 and gave the company an “equal weight” rating in a report on Monday, May 6th. UBS Group lifted their price target on DaVita from $113.00 to $134.00 and gave the company a “buy” rating in a research note on Wednesday, February 14th. Truist Financial lifted their price target on DaVita from $135.00 to $150.00 and gave the company a “hold” rating in a research note on Wednesday, May 15th. TheStreet upgraded DaVita from a “c+” rating to a “b-” rating in a research note on Wednesday, February 7th. Finally, StockNews.com downgraded DaVita from a “strong-buy” rating to a “buy” rating in a research note on Monday, May 6th. Two equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat, DaVita has a consensus rating of “Moderate Buy” and a consensus target price of $144.67.

DaVita Stock Up 4.8 %

DVA opened at $138.54 on Friday. The business’s fifty day moving average is $135.26 and its two-hundred day moving average is $119.00. The company has a debt-to-equity ratio of 7.95, a quick ratio of 1.37 and a current ratio of 1.43. The company has a market cap of $12.15 billion, a price-to-earnings ratio of 15.74, a PEG ratio of 1.06 and a beta of 1.04. DaVita Inc. has a one year low of $71.51 and a one year high of $145.04.

DaVita (NYSE:DVA) last issued its quarterly earnings data on Thursday, May 2nd. The company reported $2.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.95 by $0.43. DaVita had a return on equity of 68.52% and a net margin of 6.61%. The business had revenue of $3.07 billion for the quarter, compared to the consensus estimate of $3.03 billion. During the same period in the prior year, the business earned $1.58 earnings per share. The business’s revenue was up 6.9% on a year-over-year basis. Analysts anticipate that DaVita Inc. will post 9.62 EPS for the current fiscal year.

Insider Activity

In related news, Director Barbara J. Desoer sold 5,030 shares of the company’s stock in a transaction on Friday, May 10th. The stock was sold at an average price of $138.81, for a total value of $698,214.30. Following the completion of the transaction, the director now directly owns 10,954 shares in the company, valued at $1,520,524.74. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, Director Barbara J. Desoer sold 5,030 shares of the company’s stock in a transaction on Friday, May 10th. The stock was sold at an average price of $138.81, for a total value of $698,214.30. Following the completion of the transaction, the director now directly owns 10,954 shares in the company, valued at $1,520,524.74. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Javier Rodriguez sold 67,603 shares of the company’s stock in a transaction on Monday, February 26th. The shares were sold at an average price of $126.11, for a total value of $8,525,414.33. Following the completion of the transaction, the chief executive officer now owns 488,697 shares of the company’s stock, valued at $61,629,578.67. The disclosure for this sale can be found here. Company insiders own 2.00% of the company’s stock.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.